Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 30 Aug 2026	HK$721.5b	HK$537.6b	HK$33.0b	15.2x	21.9x	1.3x
Tue, 28 Jul 2026	HK$676.3b	HK$522.4b	HK$28.0b	14.4x	24.2x	1.3x
Thu, 25 Jun 2026	HK$608.4b	HK$519.4b	HK$29.1b	13.3x	20.9x	1.2x
Sat, 23 May 2026	HK$696.9b	HK$520.6b	HK$29.6b	14.4x	23.6x	1.3x
Mon, 20 Apr 2026	HK$796.1b	HK$518.8b	HK$30.0b	15.3x	26.5x	1.5x
Wed, 18 Mar 2026	HK$745.3b	HK$499.9b	HK$30.5b	12.3x	24.4x	1.5x
Fri, 13 Feb 2026	HK$822.6b	HK$497.8b	HK$30.5b	13.2x	27x	1.7x
Sun, 11 Jan 2026	HK$849.6b	HK$491.3b	HK$30.1b	13.4x	28.2x	1.7x
Tue, 09 Dec 2025	HK$825.5b	HK$484.5b	HK$29.7b	13.6x	27.8x	1.7x
Thu, 06 Nov 2025	HK$790.7b	HK$480.2b	HK$29.8b	13.9x	26.5x	1.6x
Sat, 04 Oct 2025	HK$816.5b	HK$479.6b	HK$30.6b	13.7x	26.7x	1.7x
Mon, 01 Sep 2025	HK$793.1b	HK$479.8b	HK$30.6b	13.1x	25.9x	1.7x
Wed, 30 Jul 2025	HK$782.0b	HK$475.6b	HK$29.1b	12.1x	26.9x	1.6x
Fri, 27 Jun 2025	HK$634.7b	HK$477.4b	HK$28.9b	11.9x	22x	1.3x
Sun, 25 May 2025	HK$558.7b	HK$477.8b	HK$29.2b	10.7x	19.2x	1.2x
Tue, 22 Apr 2025	HK$473.0b	HK$467.0b	HK$28.6b	10.1x	16.5x	1x
Thu, 20 Mar 2025	HK$483.8b	HK$466.0b	HK$32.2b	9x	15x	1x
Sat, 15 Feb 2025	HK$429.9b	HK$463.2b	HK$31.9b	8.6x	13.5x	0.9x
Mon, 13 Jan 2025	HK$399.8b	HK$459.0b	HK$31.7b	7.9x	12.6x	0.9x
Wed, 11 Dec 2024	HK$444.1b	HK$463.3b	HK$31.9b	8.3x	13.9x	1x
Fri, 08 Nov 2024	HK$450.8b	HK$468.8b	HK$32.5b	8.6x	13.9x	1x
Sun, 06 Oct 2024	HK$532.0b	HK$474.8b	HK$33.0b	8.3x	16.1x	1.1x
Tue, 03 Sep 2024	HK$439.7b	HK$473.0b	HK$32.8b	7.9x	13.4x	0.9x
Thu, 01 Aug 2024	HK$423.5b	HK$460.9b	HK$32.7b	7.5x	13x	0.9x
Sat, 29 Jun 2024	HK$438.9b	HK$461.6b	HK$33.7b	8.2x	13x	1x
Mon, 27 May 2024	HK$459.0b	HK$463.0b	HK$33.7b	8.5x	13.6x	1x
Wed, 24 Apr 2024	HK$436.5b	HK$464.3b	HK$33.8b	7.3x	12.9x	0.9x
Fri, 22 Mar 2024	HK$467.9b	HK$470.5b	HK$32.5b	7.9x	14.4x	1x
Sun, 18 Feb 2024	HK$433.2b	HK$471.0b	HK$33.6b	7x	12.9x	0.9x
Tue, 16 Jan 2024	HK$452.0b	HK$471.9b	HK$33.7b	7.7x	13.4x	1x
Thu, 14 Dec 2023	HK$482.0b	HK$471.6b	HK$33.7b	7.6x	14.3x	1x
Sat, 11 Nov 2023	HK$487.0b	HK$469.2b	HK$31.9b	7x	15.3x	1x
Mon, 09 Oct 2023	HK$424.5b	HK$469.6b	HK$31.6b	6.7x	13.4x	0.9x
Wed, 06 Sep 2023	HK$427.8b	HK$469.7b	HK$31.6b	6.9x	13.5x	0.9x

Current Industry PE

Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 21.4x which is higher than its 3-year average PE of 18.7x.

The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.3x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have grown 2.3% per year over the last three years.
Revenues for these companies have grown 4.8% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?


HK Market	-0.088%
Healthcare	1.23%
Pharma	3.12%
Pharma	3.12%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
3692 Hansoh Pharmaceutical Group	HK$36.72	11.0% +HK$22.1b	1.9%	PE28.6x
1093 CSPC Pharmaceutical Group	HK$9.53	3.7% +HK$3.9b	-5.4%	PE12.6x
2630 Vigonvita Life Sciences	HK$99.65	14.3% +HK$2.1b	n/a	PS66x
2005 SSY Group	HK$2.70	8.9% +HK$636.1m	-5.1%	PE15.4x
1681 Consun Pharmaceutical Group	HK$14.13	3.9% +HK$438.8m	-5.1%	PE8.7x

Company

Last Price

Valuation

3692 Hansoh Pharmaceutical Group

HK$36.72

11.0%
+HK$22.1b

1.9%

PE28.6x

1093 CSPC Pharmaceutical Group

HK$9.53

3.7%
+HK$3.9b

-5.4%

PE12.6x

2630 Vigonvita Life Sciences

HK$99.65

14.3%
+HK$2.1b

n/a

PS66x

2005 SSY Group

HK$2.70

8.9%
+HK$636.1m

-5.1%

PE15.4x

1681 Consun Pharmaceutical Group

HK$14.13

3.9%
+HK$438.8m

-5.1%

PE8.7x

CF PharmTech, Inc. Announces Expansion of Indications of ICF001 Following Receipt of Implied Clinical Trial Approvals from the NMPA

CF PharmTech, Inc. announced that ICF001, a self-developed long-acting inhaled dry powder candidate, has obtained implied clinical trial approvals from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in interstitial lung disease, namely idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. These approvals follow the NMPA’s implied clinical trial approvals obtained in March 2026 for the product to conduct clinical trials in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The product is now cleared to enter clinical studies across four indications spanning pulmonary vascular disease and progressive fibrosing lung disease. The four indications of the product are expected to be developed from a common molecule, formulation, device and clinical pharmacology platform. Based on the company’s preclinical and formulation work to date, the current design objective is to split the daily dose into two administrations (that is, twice-daily dosing), with the intention of maintaining coverage throughout the dosing interval while moderating peak exposure and allowing flexibility in dose adjustment or temporary interruption. In China, treatment of pulmonary arterial hypertension has moved towards combination therapy across multiple mechanisms, but the availability of inhaled and long-acting prodrug products remains limited, and unmet clinical need persists across pulmonary hypertension associated with interstitial lung disease, idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. If the product completes clinical development successfully and obtains marketing approval, the company intends to draw on its domestic research and development, inhalation manufacturing and commercial capabilities to support patient access. The company plans to conduct Phase I trials in China and, subject to obtaining the necessary approvals from the relevant overseas regulatory authorities, overseas. The company currently intends to explore possible global multi-centre development, regional licensing, co-development or other forms of collaboration in the future. The company will assess potential opportunities having regard to the maturity of the clinical data. Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. There is no assurance that the approval of clinical trials will result in the achievement of successful clinical results, the grant of marketing approval or the realization of commercialization.

Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

First half 2026 earnings released: EPS: HK$0.11 (vs HK$0.096 in 1H 2025)

First half 2026 earnings released

First half 2026 earnings released

First half 2026 earnings released

First half dividend of HK$0.93 announced

Here's What Analysts Are Forecasting For Hansoh Pharmaceutical Group Company Limited (HKG:3692) After Its Half-Year Results

First half 2026 earnings released: EPS: CN¥0.025 (vs CN¥0.011 in 1H 2025)

First half dividend of HK$0.38 announced

Investor sentiment improves as stock rises 19%

First half 2026 earnings: EPS and revenues miss analyst expectations

First half 2026 earnings released: EPS: CN¥0.33 (vs CN¥0.25 in 1H 2025)

CF PharmTech, Inc. Announces Expansion of Indications of ICF001 Following Receipt of Implied Clinical Trial Approvals from the NMPA

Sunshine Lake Pharma Co., Ltd. Provides Group Earnings Guidance for the Six Months Ended June 30, 2026

Now 21% undervalued

First half dividend of HK$0.19 announced

The United Laboratories International Holdings Limited to Report First Half, 2026 Results on Aug 31, 2026